ENANTA PHARMACEUTICALS INC
ENTANASDAQTrading Snapshot
- Day Range
- $11.28 – $11.82
- 52-Week Range
- $10.22 – $17.15
- Volume (shares)
- 33,068.784
- Avg Volume (shares)
- —
- Shares Outstanding
- 29.1M
- Next Earnings
- 2026-11-16
Fundamentals Snapshot
- Annual Revenue
- $65M
- Last Q Revenue
- $14M
- P/E Ratio
- —
- P/S Ratio
- 5.4x
- EPS (TTM)
- $-2.41
- Dividend Yield
- —
- Dilution (1yr)
- +35.4%
ENANTA PHARMACEUTICALS INC
ENTA
StockOtter · stockotter.spaceAbout ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today anno
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, tod
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two compa
Bank of America Corp DE Reduces Stake in Enanta Pharmaceuticals, Inc. $ENTA
Bank of America Corp DE cut its stake in Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) by 59.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,5
Enanta Pharmaceuticals to Participate in September Investor Conferences
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections